MAY 14, 2020 7:52 PM PDT

Therapeutic for Gastrointestinal Tumors

WRITTEN BY: Nouran Amin

The FDA has approved ripretinib (Qinlock) which is the first drug for fourth-line treatment of advanced gastrointestinal stromal tumors (GIST). The therapeutic is approved for use in adults who have previously received treatment with 3 or more kinase inhibitor therapies, including imatinib, sunitinib, and regorafenib. When patients do not respond to these treatments, they may be prescribed Qinlock.

GIST results when abnormal cells form in the tissues of the gastrointestinal tract. These tumors most likely form in the stomach, small intestine, and large intestine.

Learn more about GIST, which affects roughly 6,000 adults annually in the United States:

“GIST is a complex disease and the majority of patients who initially respond to traditional tyrosine kinase inhibitors eventually develop tumor progression due to secondary mutations,” said Margaret von Mehren, MD, chief of sarcoma oncology and associate director for clinical research at Fox Chase Cancer Center.

Treatment for GIST using Qinlock was granted approval after findings of the INVICTUS study through the Fast Track designation and Priority Review by the FDA, in addition to the Breakthrough Therapy designation.

Some noted side-effects of Qinlcok use includes alopecia, fatigue, vomiting, and a variety of additional gastrointestinal complications. Treatment may also adversely affect a developing fetus during pregnancy and may be a risk for skin cancer, hypertension, and cardiac dysfunction.

“In the INVICTUS study, Qinlock has demonstrated compelling clinical benefit in progression-free and overall survival. Qinlock is well tolerated and is a crucial new therapy for these patients with a high unmet need.”

Source: AJMC

About the Author
  • Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JUN 26, 2021
Cancer
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
JUN 26, 2021
Immunotherapy Drug Shows Promise for Obese Patients with Breast Cancer
Research shows that obese patients with cancers including ovarian and melanoma may respond better to a certain kind of i ...
JUL 21, 2021
Drug Discovery & Development
A diet rich in phytoestrogens can help combat inflammation in multiple sclerosis.
JUL 21, 2021
A diet rich in phytoestrogens can help combat inflammation in multiple sclerosis.
Close to one million people in the United States are living with multiple sclerosis (MS). MS is a chronic, neuroinflamma ...
JUL 29, 2021
Drug Discovery & Development
A low-cost drug for the treatment of hepatitis.
JUL 29, 2021
A low-cost drug for the treatment of hepatitis.
      The viral disease, Hepatitis C, is known as a silent killer. Hepatitis C is easily spread thro ...
AUG 07, 2021
Cancer
New Drug Combo Eliminates Pancreatic Cancer in Mice
AUG 07, 2021
New Drug Combo Eliminates Pancreatic Cancer in Mice
A combination of three immunotherapy drugs can eliminate pancreatic tumors in mice. The study was published in Canc ...
AUG 15, 2021
Drug Discovery & Development
Diabetes Drug May Reduce Alzheimer's Risk
AUG 15, 2021
Diabetes Drug May Reduce Alzheimer's Risk
People who take a drug used to lower blood sugar levels in type 2 diabetes have less amyloid-beta in their brains, a bio ...
AUG 25, 2021
Chemistry & Physics
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
AUG 25, 2021
Self-Assembling Molecules: A Potential "One-Size-Fits-All" Cancer Therapy
A new study from the University of Huddersfield shows promising breakthroughs on the use of self-assembling molecules as ...
Loading Comments...